SynBiotic SE (DUSE:SBX)

Germany · Delayed Price · Currency is EUR

1.260

-0.122 (-8.83%)

At close: Jun 22, 2026

-64.90% (1Y)

Market Cap	8.39M -61.1%
Revenue (ttm)	3.86M -52.7%
Net Income	-10.63M
EPS	-2.24
Shares Out	n/a
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	1,000
Open	1.290
Previous Close	1.382
Day's Range	1.248 - 1.290
52-Week Range	1.248 - 3.710
Beta	n/a
Analysts	Strong Buy
Price Target	6.05 (+380.16%)
Earnings Date	n/a

About SynBiotic SE

SynBiotic SE engages in the research and development, production, and marketing of cannabinoid and terpene-based solutions to for pain, sleep deprivation, and anxiety. It also offers hemp, cannabinoids, dietary supplements, and cosmetic products; medical cannabis products; and cannabis products for recreational use under the Hempamed, Princess Stardust, The Hempany, and Hempamed Rx brand names. The company was formerly known as Ledgertech SE and changed its name to SynBiotic SE. SynBiotic SE was founded in 2017 and is based in Munich, Germany. [Read more]

Industry Pharmaceutical Preparations

Founded 2017

Employees 55

Stock Exchange Dusseldorf Stock Exchange

Ticker Symbol SBX

Full Company Profile

Financial Performance

In 2023, SynBiotic SE's revenue was 3.86 million, a decrease of -52.71% compared to the previous year's 8.17 million. Losses were -10.63 million, -56.36% less than in 2022.

Financial Statements

Analyst Summary

According to 2 analysts, the average rating for SBX stock is "Strong Buy." The 12-month stock price target is €6.05, which is an increase of 380.16% from the latest price.

Price Target

€6.05

(380.16% upside)

Analyst Consensus: Strong Buy

Stock Forecasts